## -online.com genomics





### Human CD22 CRISPR gRNA + Cas9 in Lenti Particles

| Overview              |  |
|-----------------------|--|
| Quantity:             | 300 μL   |
| Gene:                 | CD22   |
| Species:              | Human  |
| Insert:               | gRNA + Cas9  |
| Vector:               | Lentiviral Vector  |
| Application:          | Protein Expression (PExp), Genome Editing with Engineered Nucleases (GEEN)   |
| Product Details       |  |
| Purpose:              | Individual gRNA against CD22 in Lentiviral Particles with a Titer of >1x10e7 IU/mL. (sgRNA and Cas9 in a single vector)  |
| Vector Backbone:      | pLenti-U6-sgRNA-SFFV-Cas9-2A-Puro  |
| Promoter:             | U6 Promoter, SFFV Promoter   |
| Selectable Marker:    | Puromycin  |
| Bacterial Resistance: | Ampicillin   |
| Expression Type:      | Stable, Transient  |
| Sequence:             | Sequence available upon placing order  |
| Specificity:          | GRNAs are designed for use with Cas9 Nuclease only.  Cas9 Nuclease is under the control of the SFFV promoter which should work for a vast majority of cells, except ES cells or iPS cells. |
| Sequencing Primer:    | U6 Forward Primer: 5'TACGTCCAAGGTCGGGCAGGAAGA-3'   |
| Components:           | Lentiviral particles with an individual gRNA (300 μL) for a specific sequence of CD22  |

# Target Details Gene: CD22 Alternative Name: CD22 (CD22 Products) NCBI Accession: NM\_001771 Application Details Application Notes: Recommended for quality control: Restriction Enzyme Digest and Sequencing Restrictions: For Research Use only

### Handling

| Format:      | Viral Particles |
|--------------|-----------------|
| Storage:     | -80 °C          |
| Expiry Date: | 12 months       |

#### Publications

| Product cited in: | Johnson, Drugan, Miller, Evans: "38" in: , Vol. 1363, Issue Nucleic acids research, pp. 28-39, ( |
|-------------------|--|
|                   | 1991)  |